Protagenic Therapeutics (NASDAQ:PTIX) Releases Quarterly Earnings Results

Protagenic Therapeutics (NASDAQ:PTIX) issued its quarterly earnings data on Monday. The company reported ($0.24) earnings per share for the quarter, Zacks reports.

Protagenic Therapeutics Stock Down 1.6 %

NASDAQ:PTIX opened at $0.25 on Wednesday. Protagenic Therapeutics has a fifty-two week low of $0.18 and a fifty-two week high of $1.87. The firm’s 50 day moving average is $0.30 and its two-hundred day moving average is $0.48. The company has a market cap of $1.78 million, a P/E ratio of -0.20 and a beta of 0.43.

Protagenic Therapeutics Company Profile

Protagenic Therapeutics, Inc, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses.